Literature DB >> 26968647

Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry.

Cajetan Dogo-Isonagie1, Su-Lin Lee1, Katheryn Lohith1, Hongbing Liu1, Sivakoteswara R Mandadapu1, Sabrina Lusvarghi1, Robert D O'Connor1, Carole A Bewley2.   

Abstract

In the absence of a cure or vaccine for HIV/AIDS, small molecule inhibitors remain an attractive choice for antiviral therapeutics. Recent structural and functional studies of the HIV-1 surface envelope glycoprotein gp120 have revealed sites of vulnerability that can be targeted by small molecule and peptide inhibitors, thereby inhibiting HIV-1 infection. Here we describe a series of small molecule entry inhibitors that were designed to mimic the sulfated N-terminal peptide of the HIV-1 coreceptor CCR5. From a panel of hydrazonothiazolyl pyrazolinones, we demonstrate that compounds containing naphthyl di- and tri-sulfonic acids inhibit HIV-1 infection in single round infectivity assays with the disulfonic acids being the most potent. Molecular docking supports the observed structure activity relationship, and SPR confirmed binding to gp120. In infectivity assays treatment with a representative naphthyl disulfonate and a disulfated CCR5 N-terminus peptide results in competitive inhibition, with combination indices >2. In total this work shows that gp120 and HIV-1 infection can be inhibited by small molecules that mimic the function of, and are competitive with the natural sulfated CCR5 N-terminus. Published by Elsevier Ltd.

Entities:  

Keywords:  CCR5 N-terminus; Competitive inhibition; HIV co-receptors; Molecular docking; Tyrosine sulfate

Mesh:

Substances:

Year:  2016        PMID: 26968647      PMCID: PMC7261409          DOI: 10.1016/j.bmc.2016.02.044

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  30 in total

1.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 2.  V3: HIV's switch-hitter.

Authors:  Oliver Hartley; Per Johan Klasse; Quentin J Sattentau; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2005-02       Impact factor: 2.205

Review 3.  The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection.

Authors:  E O Freed; M A Martin
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

4.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

5.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Eur J Biochem       Date:  1981-03-16

6.  Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.

Authors:  S Rusconi; M Moonis; D P Merrill; P V Pallai; E A Neidhardt; S K Singh; K J Willis; M S Osburne; A T Profy; J C Jenson; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

7.  Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.

Authors:  Priyamvada Acharya; Cajetan Dogo-Isonagie; Judith M LaLonde; Son N Lam; George J Leslie; Mark K Louder; Leah L Frye; Asim K Debnath; Jeremy R Greenwood; Timothy S Luongo; Loïc Martin; K Shawn Watts; James A Hoxie; John R Mascola; Carole A Bewley; Peter D Kwong
Journal:  ACS Chem Biol       Date:  2011-08-05       Impact factor: 5.100

8.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

9.  Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry.

Authors:  Son N Lam; Priyamvada Acharya; Richard Wyatt; Peter D Kwong; Carole A Bewley
Journal:  Bioorg Med Chem       Date:  2008-10-05       Impact factor: 3.641

10.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

View more
  1 in total

Review 1.  Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.

Authors:  Heng Wee Tan; Yan-Ming Xu; Andy T Y Lau
Journal:  Rev Med Virol       Date:  2020-06-30       Impact factor: 11.043

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.